1. Home
  2. TORO vs MDWD Comparison

TORO vs MDWD Comparison

Compare TORO & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toro Corp.

TORO

Toro Corp.

HOLD

Current Price

$4.97

Market Cap

173.8M

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$14.77

Market Cap

181.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TORO
MDWD
Founded
2022
2000
Country
Cyprus
Israel
Employees
N/A
N/A
Industry
Marine Transportation
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
173.8M
181.1M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
TORO
MDWD
Price
$4.97
$14.77
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
33.7K
80.8K
Earning Date
04-15-2026
05-20-2026
Dividend Yield
36.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$48.92
Revenue Next Year
N/A
$35.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.16
$13.54
52 Week High
$8.50
$21.26

Technical Indicators

Market Signals
Indicator
TORO
MDWD
Relative Strength Index (RSI) 45.83 48.72
Support Level $4.89 $13.65
Resistance Level $5.85 $14.99
Average True Range (ATR) 0.28 0.51
MACD 0.00 0.16
Stochastic Oscillator 36.99 58.59

Price Performance

Historical Comparison
TORO
MDWD

About TORO Toro Corp.

Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: